Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Business Wire
- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna - SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced two oral presentations and a poster presentation with data relevant to seralutinib at the European Respiratory Society (ERS) Congress 2024, which takes place from September 7th through 11th online and onsite in Vienna, Austria.“We are thrilled to present additional findings from our Phase 2 TORREY open-label extension study at the European Respiratory Society Conference in Vienna which highlight the sustained effect of seralutinib beyond 24 weeks of treatment,” said Faheem Hasnain, Co-Founder, CEO, and Chairman of Gossamer Bio.“With the continued improvement in clinical outcome measu
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) [Yahoo! Finance]Yahoo! Finance
- Industry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue Forecasts [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
GOSS
Earnings
- 8/12/24 - Miss
GOSS
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form SC
- 11/7/24 - Form 8-K
- GOSS's page on the SEC website